Perrigo Surpasses Q2 Earnings, Stock Slides on 2025 Sales Cut

Perrigo's Q2 2025 Earnings Performance

Perrigo, known by its ticker symbol PRGO, released its second-quarter earnings for 2025, reporting adjusted earnings of 57 cents per share. This fell short of the Zacks Consensus Estimate of 59 cents. Despite this, the figure represented a 7.5% year-over-year increase, largely attributed to reduced interest expenses.

Net sales for the quarter stood at $1.06 billion, a 0.9% decline from the previous year. This was below the Zacks Consensus Estimate of $1.08 billion. The drop in sales was primarily due to the loss of revenue from exited businesses and product lines, although favorable currency movements helped offset some of the decline.

During the quarter, sales decreased by 2.5% year over year because of the exit of certain businesses and product lines. However, this was partially counterbalanced by a 1.7% gain from favorable currency impacts. At constant currency, which excludes foreign exchange effects, sales fell by 2.6%. Organic net sales, which exclude the effects of acquisitions, divestitures, and currency fluctuations, declined by 0.1%.

Segment Analysis

Perrigo reports its results through two main segments: Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI).

CSCA:
The CSCA segment reported net sales of $622 million for the quarter, reflecting a 1.9% year-over-year decline. While sales grew in the Nutrition, Healthy Lifestyle, and Upper Respiratory categories, these gains were more than offset by lower sales in Digestive Health and Oral Care. Organic net sales also dropped by 1.9%, and the segment’s performance fell below both the Zacks Consensus Estimate of $636 million and the model estimate of $641 million.

CSCI:
The CSCI segment reported net sales of $434 million, marking a 0.7% increase compared to the same period last year. This growth was driven by favorable currency translation and organic sales growth. However, this was partially offset by the negative impact of divested businesses and exited product lines. At constant currency, sales fell by 3.5% year over year. Organically, sales increased by 2.7%, but the segment still missed the Zacks Consensus Estimate and the model estimate of $445 million and $439 million, respectively.

2025 Guidance and Market Reaction

Perrigo has revised its financial guidance for 2025, citing challenges in the infant formula industry and shifting consumer trends. As a result, the company now expects total sales to grow toward the lower end of its previously issued range of 0-3%. This revision likely contributed to a 6% drop in the company’s stock price during pre-market trading.

Year-to-date, Perrigo’s shares have gained 4%, slightly underperforming the broader industry, which saw a 5% increase.

Strategic Measures and Financial Outlook

Despite the downward revision in top-line expectations, Perrigo remains confident in its ability to manage costs. The company anticipates that tariffs will increase expenses, particularly in its Oral Care segment, which relies heavily on Chinese sourcing. However, it believes the impact will be manageable. With 85% of its finished goods produced in the United States, Perrigo plans to mitigate pressure through price adjustments, domestic production shifts, and other supply-chain strategies.

Perrigo has reiterated its 2025 financial targets, including an adjusted EPS range of $2.90 to $3.10, an adjusted gross margin of approximately 40%, and an adjusted operating margin near 15%.

Zacks Rank and Investment Outlook

Perrigo currently holds a Zacks Rank of #2, indicating a "Buy" rating. This reflects confidence in the company’s long-term prospects despite recent challenges.

Other Biotech Stocks to Watch

In addition to Perrigo, several biotech stocks have received strong investment ratings:

• CorMedix (CRMD): Holding a Zacks Rank of #1 ("Strong Buy"), CorMedix has seen a 49% year-to-date increase. Its 2025 EPS estimates have risen from 93 cents to 97 cents over the past 60 days.
• Genmab (GMAB): Also with a Zacks Rank of #1, Genmab’s shares have gained 6% so far this year. Its 2025 EPS estimates have improved from $1.51 to $1.58.
• Immunocore (IMCR): Ranking as a Zacks #1 stock, Immunocore’s shares have climbed 10% year to date. Its 2025 loss per share estimates have improved from 86 cents to 68 cents.

These companies have shown strong earnings performance, with CorMedix and Immunocore consistently beating estimates in recent quarters.